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The role of minor histocompatibility antigens in
GVHD and rejection: a mini-review
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Immunohaematology and Bloodbank, University Hospital Leiden, The Netherlands
'Ihe success of HLA genotypically identical
bone marrow grafting is still hampered by
graft-versus-host disease (GVHD) and
rejection of the graft. One of the causes of
the latter complications could be attributed
to minor histocompatibility (mH) antigen
disparities between the HLA identical
sitolings (1).
In this mini-review we will share our current
Knowledge on the possible impacts of human mH
antigen disparities between HLA identical
donor and recipient on the outcome of bone
marrow transplantation.
mH Anticrens and Graft Rejection
With regard to the possible influence of mH
antigens on bone marrow graft rejection,
expression of mH antigens on haematopoietic
stem cells (HPC) might be relevant in
presensitized patients receiving a mH antigen
positive Τ cell depleted marrow graft. For
that purpose, the expression of the male
specific antigen H-Y, the first mH antigen
known to play a role in HLA identical but sex
mismatched bone marrow exchange (2), was
studied for its expression on HPC. It became
clear that indeed H-Y is expressed on
CFU-GEMM, CFU-GM and BFU-E (3). Experiments
carried out to study the expression of other
(non sex-linked) mH antigens (designated HA-l
to HA-5, see below) demonstrated differential
expression of the latter antigens, namely
only HA-3 appeared to be expressed on HPC
(4).
We recently descrxbed a case study favoring
the supposition that expression of mH
antigens on HPC might negatively influence
engraftment (5). The occurrence of a graft
rejection in a female bone marrow transplant
recipient of a Τ lymphocyte depleted graft
fron her phenotypically HLA identical father
was analyzed in detail. Despite very
intensive conditioning regimens, residual
recipient's derived cytotoxic Τ lymphocytes
(CTL) directed againsc mH antigens expressed
on peripheral blood lymphocytes and on donor
haematopoietic progenitor cells remained and
may be responsible, for this graft failure
(5).
mH Antiaens and GVHD
The aetiology of GVHD presumes that
immunocompetent donor Τ cells are reacting
against the host tissues. Although the
precise nature of the ccmposition of the
effector cells mediating the host attack is
still unknown, one may conclude from the
experimental animal data that both the
Lyt2+ and the I^T^ Τ cell subsets
cause GVHD to mH antigen differences (6-10;
for detailed Information see elsewhere in
this volume: Korngold et al.). LdJcewise in
man, reporte on CD8 depleted marrow grafting
(11-13) indicated a prime role for the latter
subset in the pathogenesis of GVHD.
Nonetheless, these studies also pointed to a
role of the CD4 Τ cell subset in the acute
phase of GVHD.
Our in vitro studies indeed demonstrate
anti-host Τ cell reactivities in patients'
blood samples taken after HLA identical bone
marrow transplantation. Anti-host CTLs were
always observed in patients suffering from
chronic GVHD, whereas anti-host proliferative
Τ cells (Th) were mainly found in patients
with acute GVHD (14,15). Both CTL and
proliferative Τ cell activities are directed
against non-MHC or mH antigens for which the
HLA identical patient and donor differed.
LdJcewise, Tsoi et al. (16) and Irle'et al.
(17) demonstrated the presence of mH antigen
specific proliferative Τ cells in patients
suffering from GVHD. Subsequently, by the
use of selective depleted Τ cell subsets we
showed that the anti-host Th cell responses
are mediated by CD4+ve class II (HLA-DR and
-DP) restricted Τ cells (18); the anti-host
CTL responses have the CDS phenotype and
recognize the mH antigens in the context of
class I (HLA-A or -B) molecules (1, and
unpublished observations).
Immunogenetics andmH Anticrens HA-l to HA-5;
Clonal Analvsis
Five out of 21 anti-host cytotoxic effector
cell populations were previously analyzed.
These five cytotoxic Τ cell lines were
derived from five different patients. They
recognized mH antigens designated as HA-l,
-2, -3, -4 and -5 in a classical MHC
restricted fashion, whereby HA-l, -2, -4 and
-5 use HLA-A2 as restriction molecule and mH
antigen HA-3 appeared to be recognized in
association with HIA-Al (1). We recently
generated CTL clones specific for these five
non sex-linked mH antigens. With the usage
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of the latter CTL clones, immunogenetic
studies were carried out to determine the mH
antigen gene frequencies and to make an
inventory in each of the five patients of mH
antigen HA-1, -2, -3, -4 and -5 specific
anti-host CTL responses after ΕΜΓ. With
regard to the latter, we acquired from each
of three OTL lines (anti HA-1, anti HA-4,
anti HA-5 which were derived from 3 different
patients) one clone specific for the mH
antigen HA-1. Ohis observation favors the
existence of immunodominant mH antigens
(manuscript submitted for publication).
Performance of population (N=100) genetic
analysis revealed that some appeared most
frequent (72-90%) whereas other mH antigens
occurred with lesser frequencies (8-16%) in
the healthy population (manuscript submitted
for publication).
mH Antiqen Typing is not limited by MHC
Restriction
Evidently, absence of the required MHC class
I restricting antigen hampers adequate
genetic analysis. Litewise, prospective
typing of patients and their potential donors
using our Τ cell clones specific for mH
antigens is limited to those individuals
carrying the required HLA molecule. In
search of solving the latter deficit, we have
used electroporation to introduce cloned HLA
genes into the cells of interest. From our
recent studies we may conclude that gene
transfection has proven to be a reliable
technique for adequate mH antigen recognition
and consequently circumvents the deficit of
required HLA molecules in mH antigen typing
(manuscript submitted for publication).
Differential mH Antiqen Expression in the
Skin
Finally, we would lüce to briefly touch upon
one of the affected organs during GVHD after
bone marrow grafting, naraely the skin.
Following histopathological studies, it
becomes clear that dermal and epidermal
Infiltration by CD8+ cells correlate with the
severity of GVHD (19-22) whereby
keratinocytes appeared to be a target for the
GVHD attack (23). Following phenotypic and
functional in vitro analysis however, CD4 Τ
cells appeared to be clearly present as well
expression
HLA-A2+ve
experiments
HLA-A2-ve
among the skin infiltrating cells (24-26).
The antigenic target structures involved
could be tissue specific antigens on
epithelial but not on lymphoid cells like in
the studies of Tsoi et al. (27). On the
other nand, they could be mH antigenic
structures possessing a broad tissue
distribution. Therefore, we aimed at
investigating the expression of mH antigens
on keratinocytes (K) by studying their
susceptibility to lysis by our MHC restricted
H-Y and mH antigen HA-1 to -5 specific CTLs.
Hence, a modified Cr release was
developed wherein cultured human Κ could be
used as target cells (28). Next, the
of the minor Η antigen H-Y on male
Κ was explored. From our
it became clear that male
Κ are susceptible to lysis by
HLA-A2 restricted H-Y specific CTLs; the
specific recognition is clearly enhanced by
IFNy treatment of Κ (29) . With regard to the
other mH antigens HA-1 to HA-5, our recent
studies revealed expression of the mH antigen
HA-3 on human Κ (30, and manuscript in
preparation).
To get insight into the mH antigen as target
structure for GVHD as well their local
function, we currently investigate the
expression of mH antigens on different
tissues. It is noteworthy that the H-Y
specific MHC restricted cytotoxic Τ cell
clones, originally derived from and selected
for its reactivity against peripheral blood
lymphocytes (l), react so far with "Y
peptide(s)/MHC class I complexes" expressed
on male cells derived from a series of
different tissues (unpublished observations).
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